
Weight Loss & Liver Support

Goal

Weight loss & Liver Support (formerly FatRelease) contains natural substances known to support the health and proper functioning of the liver, especially when unwanted fat accumulates as a result of weight gain which subsequently leads to non-alcoholic fatty liver disease (NAFLD).¹ Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH) are increasingly common chronic liver diseases closely associated with diabetes and overweight/obesity which have reached epidemic proportions in developed countries. Reports on the prevalence of NAFLD have suggested that 27-34% of the general population in the U.S. and 40-90% of the obese population worldwide have this disease.²

Rationale

A liver is termed “fatty liver” if lipids account for more than 5% of its weight. Beyond weight gain itself, the mechanisms for the development of fatty liver are varied. A reduction in the hepatic oxidation of fatty acids because of mitochondrial dysfunction can lead to microvesicular steatosis. Another mechanism is related to an imbalance between fat uptake and secretion, with high insulin-to-glucagon ratio states leading to macrovesicular steatosis.³ These conditions “clog” the liver, disrupting its ability to convert food to energy and utilize fat. Diet, weight loss and specific nutrient ingredients such as choline, milk thistle (silymarin), N-acetyl-cysteine (NAC) have been shown to be successful in the prevention and management of fatty liver disease.^{1,2,3,4,5} Also contained in this product is Epigallocatechin gallate (EGCG) from green tea for its potential hepatic protection including antioxidant properties.^{5,6,7} *Irvingia gabonensis* has been included in this formula for its potential to improve weight loss results and related metabolic outcomes.^{8,9}

In summary, weight gain and/or poor eating habits often lead to a fatty liver, which increases the oxidative stress on this vital organ and compromises its overall functioning including inhibiting the body's ability to control proper usage/burning of sugar and fat.^{1,2,10,11,12,13}

Choline is a water-soluble essential nutrient.¹⁴ It is an important phospholipid component of the cell membrane and is the precursor molecule for the neurotransmitter acetylcholine. Choline has important roles in fat metabolism in the liver including promoting lipid (fat) transport from the liver.^{15,16} Thus, choline is a lipotropic agent that has been shown to hasten the removal of fat from the liver.^{17,18,19} Recently the Institute of Medicine (IOM) established the adequate intake (AI) of choline at 425-550 mg/day for women and men respectively, and that choline deficiency can have a negative impact on different disease states especially related to fatty liver.^{20,21,22} There is now evidence that current choline recommendations may be suboptimal for a large percentage of the population and that many others may have intakes below even the current recommendations.^{23,24,25,26} This fact has been highlighted in a study involving normal weight Chinese women. The results demonstrated that higher choline intakes were associated with lower risk of NAFLD.²⁷ This product contains ~400 mg of choline in a daily dose to complement shortages in normal synthesis and diet in order to reach daily levels shown to have a positive effect on managing liver health.

Milk thistle is derived from the milk thistle plant *Silybum marianum*, silymarin is a complex mixture of six major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic substances.²⁸ Milk thistle has been used safely for centuries in the treatment of liver problems including improving circulation, maintaining the integrity of liver cell membranes while increasing the liver's regenerative ability and formation of new cells.^{29,30,31,32} Milk thistle also exhibits antiviral, anti-inflammatory, and immunomodulatory functions in human liver and immune cells.^{33,34} Doses of 140-700 mg have been used safely and effectively in patients with NAFLD.^{35,36,37,38,39}

Practitioner Dietary Supplement Reference Guide – 3rd Edition

N-acetyl cysteine (NAC) is added because it acts as an antioxidant and hepatoprotectant in order to help combat oxidative stress,⁴⁰ including that brought on by accumulating fat in the liver.^{41,42} NAC works to block the propagation of lipid peroxidation and may also help in the prevention of the onset of NAFLD. A three-month clinical trial supplementing NAC improved alanine-transaminase (ALT) levels and the size of the spleen in patients with NAFLD (both markers of liver function), demonstrating its effectiveness against liver fat infiltration.⁴³

Epigallocatechin gallate (EGCG) from green tea is included because it is one of the best documented plants that have been used in the prevention of liver diseases.^{32,44} It is generally agreed upon that much of the positive health effects of green tea (GT) are mediated by its polyphenols, known as catechins.^{5,45} The major catechins in green tea are EGCG, (-)-epicatechin-3-gallate, (-)-epigallocatechin, and (-)-epicatechin. EGCG accounts for 50% to 80% of GT catechins amounting to ~200 to 300 mg per brewed cup of green tea.⁴⁶ EGCG also works as an antioxidant and has the potential to destroy fat cells⁴⁷, increase overall energy expenditure,^{48,49} and has demonstrated positive effects on fat oxidation.^{50,51,52,53,54,55} Recent findings suggest that green tea catechin consumption enhances exercise-induced changes in abdominal fat and serum triglycerides in humans⁵⁶ and in animal models.⁵⁷ Most recently Justin D Roberts, Michael G Roberts et al, using 571 mg/d of a decaffeinated GT extract (providing 400 mg/d of EGCG) for four weeks in exercisers found a 24.9% increase in fat oxidation rates, a 1.63% decrease in body fat and a 10.9% improvement in performance distance covered (20.23 KM to 22.43 KM), all compared to placebo.⁵⁸ This study strongly supports EGCG's ability alone to increase fat oxidation.

Irvingia gabonensis (AKA African Mango), a fleshy West African fruit, is common in traditional Nigerian and Cameroonian cuisine. Initial observations suggested beneficial changes in metabolic parameters (e.g. cholesterol, lipid profiles, insulin signaling, etc.) were associated with the high fiber content of *Irvingia gabonensis*.⁸ Results of later analysis suggested that those beneficial observations of *Irvingia gabonensis* (IG) could not be from fiber content alone.⁵⁹ An *in vitro* study using a validated experimental model (murine 3T3-L1 adipocytes) to determine IGs potential mechanisms of actions, provided compelling data that the *Irvingia gabonensis* seed extract may inhibit adipogenesis (activation/formation of fat cells) through modulation of peroxisome proliferator-activated receptor gamma (PPAR gamma), which regulates fatty acid storage and glucose metabolism (the genes activated by PPARG stimulate lipid uptake and adipogenesis by fat cells),⁶⁰ and modulation of glycerol-3 phosphate dehydrogenase (enzyme which serves as a link between carbohydrate and lipid metabolism). These actions are in addition to IGs potential beneficial impact upon leptin (appetite hormone) and adiponectin (involved in regulating glucose levels as well as fatty acid breakdown).⁶¹

Preliminary clinical research showed taking 1.05 grams of a crude seed extract three times daily combined with a low fat, low calorie diet of 1,800 kcal/day reduces weight by about 4 kg after four weeks, compared to no weight reduction in overweight patients taking placebo.⁸ Another preliminary clinical study (see Figure 3 below) demonstrated that a standardized seed extract (IGOB131), (also used in Weight Loss & Liver Support) taken at 150 mg twice daily for 10 weeks can reduce weight by 12.8 kg, compared to 0.7 kg in overweight patients taking a placebo.⁹ In this study, overweight patients taking *Irvingia gabonensis* (IG) consumed an average of 2,767 kcal/day compared to 3,156 kcal/day in the placebo group, suggesting favorable effects on appetite. The IG group also decreased total and LDL cholesterol levels by 26% and 27% respectively, compared with 2% and 5% with placebo. Similar results also occurred in a study using a combination of standardized *Irvingia gabonensis* seed extract (IGOB131) and *Cissus quadrangularis*, for 10 weeks in overweight adults.⁶²




Figure 3
Percentage decrease in body weight (WT), Waist size (WS), Fat (FAT), Total Cholesterol (TCHOL), LDL cholesterol (LDL), Glucose (GLU), Leptin (LEP), C-reactive protein (CRP) and Adiponectin (ADIP) after 10 weeks of use of extract IGOB131.

Typical Use

- Non-stimulant fat-loss aid
- Recommended for overweight people to support a complete weight loss program and liver health
- Can be used alone or as part of the dotFIT 90 Day Weight Loss Solution (a.k.a. LeanPak 90)
- Take one tablet, three times daily, 30 minutes before meals with at least 8 fl. oz of water
- Discontinue after reaching fat loss goal

Precautions

Weight Loss & Liver Support is generally considered a safe fat-loss aid. Theoretically, concomitant use of choline (higher doses than found in this product) and atropine may decrease the effects and side effects of atropine.⁶³ Diabetes: milk thistle constituents might lower blood glucose in patients with type 2 diabetes. People with diabetes using milk thistle products should monitor blood glucose levels very closely. Dose adjustments to diabetes medications might be necessary.^{64,65} People with liver disease should consult with their physician before using a product containing ECGC.⁶⁶

Contraindications

Weight Loss & Liver Support is contraindicated in pregnancy and lactation because of a lack of data for this population. Because of NAC, do not take if using anticoagulant drugs or nitroglycerine.

Practitioner Dietary Supplement Reference Guide – 3rd Edition

Adverse Reactions

Milk Thistle: Orally, milk thistle is usually well-tolerated.³⁹ Uncommon events may include an occasional laxative effect, nausea, diarrhea, dyspepsia, flatulence, abdominal bloating, fullness or pain.⁶⁷

EGCG: typical doses range from one to 10 cups of green tea per day without any adverse events.⁶⁸ Very high intake of green tea may cause nausea, abdominal bloating and pain, flatulence, and diarrhea. It can also cause central nervous system stimulation and adverse effects such as dizziness, insomnia, fatigue, agitation, tremors, restlessness, and confusion. These effects are more common with higher doses of green tea or green tea extract, equivalent to 5-6 liters of tea per day.⁶⁹

Choline is not likely to cause side effects at doses up to 3,000 mg/day.⁷⁰ Doses at very high levels can include sweating, a fishy body odor and gastrointestinal distress.⁷¹

Irvingia gabonensis: The only side effects reported using the specific standardized extract of *Irvingia gabonensis* (IGOB131) were flatulence, headaches, and difficulty sleeping, which were similar to the reports in the placebo group.⁹

Upper Limit/Toxicity

Choline: The UL for choline is 3,500 mg/day and the LOAEL is 7,500 mg/day.

NAC: The LD50 for NAC in mice is 7,888 mg/kg and in rats is 6,000 mg/kg. An AMES test performed on NAC was negative for mutagenicity.³¹

Milk Thistle is considered relatively safe for long-term use.⁷²

EGCG: High doses of green tea or green tea extract, equivalent to 21-25 cups of tea per day can cause gastrointestinal distress.^{73,74}

Irvingia gabonensis: no data available at this time.

Summary

Purpose

- Supplies natural substances known to support fat metabolism and liver health especially in overweight people with extra liver fat
- Non-stimulant body fat/weight reduction aid for overweight people
- For very overweight or obese people (females >32% body fat and males >22%) to support liver health

Unique Features

- The product potentially works at many different levels within the body (antioxidant, appetite, liver fat and sugar metabolism, etc.) to support the loss of body fat and overall metabolism
- Blend is proprietary to dotFIT™
- Can be used alone or as part of the dotFIT 90 Day Weight Loss Solution (aka LeanPak90)
- Manufactured in compliance with Good Manufacturing Practices (GMPs) exclusively for dotFIT, LLC

Practitioner Dietary Supplement Reference Guide – 3rd Edition

Supplement Facts Panel

Supplement Facts		
Serving Size: 1 Tablet		
Servings Per Container: 90		Amount Per Serving
		% DV
Green Tea (Camelia Sinensis) Leaf Extract [Standardized to 98% Polyphenols (196 mg), 80% Catechins (160 mg), 45% EGCG (90 mg), 2% Caffeine (naturally occurring 4 mg)]	200 mg	*
Choline (as Choline Bitartrate)	133 mg	*
N-Acetyl Cysteine	50 mg	*
Milk Thistle (Silybum Marianum L.) Seed Extract (Standardized to 80% Silymarin)	166 mg	*
Irvingia Gabonensis Seed Extract	150 mg	*

* Daily Value not established

References

- ¹ Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol*. 2013 Dec;28 Suppl 4:81-7. doi: 10.1111/jgh.12244.
- ² Veena J, Muragundla A, Sidgiddi S, Subramaniam S. Non-alcoholic fatty liver disease: need for a balanced nutritional source. *Br J Nutr*. 2014 Dec 14;112(11):1858-72. doi: 10.1017/S0007114514002591. Epub 2014 Oct 2.
- ³ Thomas R, Riley Iii, M.D., M.S. And Ahsan M. Bhatti, M.D. Preventive Strategies in Chronic Liver Disease: Part I. Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise. *Am Fam Physician*. 2001 Nov 1;64(9):1555-156
- ⁴ Tarantino G. Nutrition: a promising route for prevention and management of obesity-related nonalcoholic fatty liver disease. *Horm Mol Biol Clin Investig*. 2014 Nov;20(2):39-41. doi: 10.1515/hmbci-2014-0034.
- ⁵ Brahma N. Singh¹, Sharmila Shankar², and Rakesh K. Srivastava. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. *Biochem Pharmacol*. 2011 December 15; 82(12): 1807–1821. doi:10.1016/j.bcp.2011.07.093.
- ⁶ Hursel R, Viechtbauer W, Westerterp-Plantenga MS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. *Int J Obes (Lond)*. 2009 Sep;33(9):956-61. Epub 2009 Jul 14. Review.
- ⁷ Mak JC. Potential role of green tea catechins in various disease therapies: progress and promise. *Clin Exp Pharmacol Physiol*. 2012 Mar;39(3):265-73. doi: 10.1111/j.1440-1681.2012.05673.x
- ⁸ J. L. Ngondi, J. E. Oben, and S. R. Minka, "The effect of *Irvingia gabonensis* seeds on body weight and blood lipids of obese subjects in Cameroon," *Lipids in Health and Disease*, vol. 4, article 12, 2005
- ⁹ J. L. Ngondi, B. C. Etoundi, C. B. Nyangono, C. M. F. Mbofung, and J. E. Oben, "IGOB131, a novel seed extract of the West African plant *Irvingia gabonensis*, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation," *Lipids in Health and Disease*, vol. 8, article 7, 2009.
- ¹⁰ Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. *Metab Syndr Relat Disord*. 2008 Spring;6(1):1-7. Review.
- ¹¹ Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. *Mol Med*. 2008 Mar-Apr;14(3-4):222-31. Review.
- ¹² Schiff L, Schiff ER. *Diseases of the liver*, 6th ed. Philadelphia: JB Lippincott Company;1987.
- ¹³ Dulloo AG, Antic V, Montani JP. Ectopic fat stores: housekeepers that can overflow into weapons of lean body mass destruction. *Int J Obes Relat Metab Disord*. 2004 Dec;28 Suppl 4:S1-2.
- ¹⁴ Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, Pownall H, Farley W, Awal M, Ahn C. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. *JPEN J Parenter Enteral Nutr* 2001;25:260–8
- ¹⁵ Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. *Clin Microbiol Infect* 2013; 19: 338-348 [PMID: 23452163 DOI: 10.1111/1469-0691.12140
- ¹⁶ Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. *Curr Opin Lipidol* 2008; 19: 229-234 [PMID: 18460912 DOI: 10.1097/ MOL.0b013e3282fee935
- ¹⁷ Michel V, Yuan Z, Ramsuvar S, Bakovic M. Choline transport for phospholipid synthesis. *Exp Biol Med (Maywood)*. 2006 May;231(5):490-504. Review.
- ¹⁸ Vance DE. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. *Curr Opin Lipidol*. 2008 Jun;19(3):229-34. Review.
- ¹⁹ Russell WR, Hoyles L, Flint HJ, Dumas ME. Colonic bacterial metabolites and human health. *Curr Opin Microbiol* 2013; 16: 246-254 [PMID: 23880135 DOI: 10.1016/j.mib.2013.07.002]
- ²⁰ Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. *Nutr Rev*. 2009 Nov;67(11):615-23. Review.
- ²¹ Li Z, Vance D. Phosphatidylcholine and choline homeostasis. *J Lipid Res*. 2008;49:1187–1194.
- ²² Anthony L Guerrero, Ryan M Colvin, Amy K Schwartz, Jean P Molleston, Karen F Murray, AnnaMae Diehl, Parvathi Mohan, Jeffrey B Schwimmer, Joel E Lavine, Michael S Torbenson, and Ann O Scheimann. Choline intake in a large cohort of patients with nonalcoholic fatty liver Disease. *Am J Clin Nutr* 2012;95:892–900. Printed in USA. _ 2012 American Society for Nutrition
- ²³ Food and Nutrition Board, Institute of Medicine. *Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B-6, Vitamin B012, Pantothenic Acid, Biotin, and Choline*. Washington, D.C.: National Academy of Sciences; 1998. pp. 390–422.
- ²⁴ Penry J, Manore M. Choline: an important micronutrient for maximal endurance-exercise performance? *Int J Sport Nutr Exerc Metab*. 2008;18:191–203.

Practitioner Dietary Supplement Reference Guide – 3rd Edition

- ²⁵ Zeisel S. Choline: Critical role during fetal development and dietary requirements in adults. *Annu Rev Nutr.* 2006;26:229–250.
- ²⁶ Caudill MA. Pre- and postnatal health: evidence of increased choline needs. *J Am Diet Assoc.* 2010 Aug;110(8):1198-206. Review.
- ²⁷ Yu D, Shu XO, Xiang YB, Li H, Yang G, Gao YT, Zheng W, Zhang X. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. *J Nutr.* 2014 Dec;144(12):2034-40. doi: 10.3945/jn.114.197533. Epub 2014 Oct 15.
- ²⁸ Kim NC, Graf TN, Sparacino CM, Wani MC, and Wall ME. Complete isolation and characterization of silybins and isosilybins from milk thistle (*Silybum marianum*). *Org Biomol Chem* 1:1684–1689 2003
- ²⁹ Giese LA. Milk thistle and the treatment of hepatitis. *Gastroenterol Nurs.* 2001 Mar-Apr;24(2):95-7.
- ³⁰ Trappoliere M, Tuccillo C, Federico A, Di Leva A, Niosi M, D'Alessio C, Capasso R, Coppola F, Dauria M, Loguercio C. The treatment of NAFLD. *Eur Rev Med Pharmacol Sci.* 2005 Sep-Oct;9(5):299-304. Review.
- ³¹ Flora K, Hahn M, Rosen H, Benner K. Milk thistle (*Silybum marianum*) for the therapy of liver disease. *Am J Gastroenterol.* 1998 Feb;93(2):139-43.
- ³² Jia Xiao, Kwok Fai So, Emily C. Liong, and George L. Tipoe. Recent Advances in the Herbal Treatment of Non-Alcoholic Fatty Liver Disease. *J Tradit Complement Med.* 2013 Apr-Jun; 3(2): 88–94. doi: 10.4103/2225-4110.110411
- ³³ Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH. Identification of hepatoprotective flavonolignans from silymarin. *Proc Natl Acad Sci U S A.* 2010 Mar 30;107(13):5995-9. Epub 2010 Mar 15.
- ³⁴ Pilar Pais • Massimo D'Amato. In Vivo Efficacy Study of Milk Thistle Extract (ETHIS-094TM) in STAMTM Model of Nonalcoholic Steatohepatitis. *Drugs R D* (2014) 14:291–299. DOI 10.1007/s40268-014-0068-2
- ³⁵ Hajaghamohammadi AA, Ziaee A, Raflei R. The efficacy of silymarin in decreasing transaminase activities in nonalcoholic fatty liver disease. A randomized controlled clinical trial. *Hepat. Mon.* 8, 191–195 (2008)
- ³⁶ Hasjiani E, Hasahemi SJ. Comparison of therapeutic effects of Silymarin and Vitamin E in nonalcoholic fatty liver disease: results of an open-label, prospective, randomized study. *JNPP* 4, 8–14 (2009).
- ³⁷ Abenavoli. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? *Expert Rev. Gastroenterol. Hepatol.* Early online, 1–3 (2013). 10.1586/17474124.2013.842893
- ³⁸ Sarah J. Schrieber,1 Roy L. Hawke, Zhiming Wen, Philip C. Smith, K. Rajender Reddy, Abdus S. Wahed, Steven H. Belle, Nezam H. Afdhal, Victor J. Navarro, Catherine M. Meyers, Edward Doo, and Michael. W. Fried. Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis C. *DRUG METABOLISM AND DISPOSITION.* Vol. 39, No. 12. DMD 39:2182–2190, 2011
- ³⁹ Pradhan, S C; Girish, C. Hepatoprotective Herbal Drug, Silymarin From Experimental Pharmacology to Clinical Medicine. April 28, 2007
- ⁴⁰ Yedjou CG, Tchounwou CK, Haile S, Edwards F, Tchounwou PB. N-acetyl-cysteine protects against DNA damage associated with lead toxicity in HepG2 cells. *Ethn Dis.* 2010 Winter;20(1 Suppl 1):S1-101-3.
- ⁴¹ Angulo P. Treatment of nonalcoholic fatty liver disease. *Ann Hepatol.* 2002 Jan-Mar;1(1):12-9. Review.
- ⁴² Kelly GS. Clinical applications of N-acetylcysteine. *Altern Med Rev.* 1998 Apr;3(2):114-27. Review.
- ⁴³ Manouchehr Khoshbaten, Akbar Aliasgarzadeh, Koorosh Masnadi, Mohammad K Tarzamani, Sara Farhang, Hosain Babaei, Javad Kiani, Maryam Zaare, Farzad Najafipoor. N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease. *Hepat Mon* 2010; 10 (1): 12-16
- ⁴⁴ Mak JC. Potential role of green tea catechins in various disease therapies: progress and promise. *Clin Exp Pharmacol Physiol.* 2012 Mar;39(3):265-73. doi: 10.1111/j.1440-1681.2012.05673.x
- ⁴⁵ Jane J. Y. Kim,1 Yi Tan,1 Linda Xiao,1 Ya-Li Sun,2 and Xianqin Qu1. Green Tea Polyphenol Epigallocatechin-3-Gallate Enhance Glycogen Synthesis and Inhibit Lipogenesis in Hepatocytes. *BioMed Research International* Volume 2013, Article ID 920128, 8 pages <http://dx.doi.org/10.1155/2013/920128>
- ⁴⁶ Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. *Cancer research.* 2006; 66:2500–5. [PubMed: 16510563]
- ⁴⁷ Lin J, Della-Fera MA, Baile CA. Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. *Obes Res.* 2005 Jun;13(6):982-90.
- ⁴⁸ Murase T, Nagasawa A, Suzuki J, Hase T, Tokimitsu I. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. *Int J Obes Relat Metab Disord.* 2002 Nov;26(11):1459-64.
- ⁴⁹ Hursel R, Viechtbauer W, Westerterp-Plantenga MS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. *Int J Obes (Lond).* 2009 Sep;33(9):956-61. doi: 10.1038/ijo.2009.135. Epub 2009 Jul 14

Practitioner Dietary Supplement Reference Guide – 3rd Edition

- ⁵⁰ Diepvens K, Westerterp KR, Westerterp-Plantenga MS. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin and green tea. *Am J Physiol Regul Integr Comp Physiol*. 2006 Jul 13; [Epub ahead of print]
- ⁵¹ Dulloo AG, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechinpolyphenols, caffeine and sympathetic activity. *Int J Obes Relat Metab Disord*. 2000 Feb;24(2):252-8.
- ⁵² Berube-Parent S, Pelletier C, Dore J, Tremblay A. Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men. *Br J Nutr*. 2005 Sep;94(3):432-6.
- ⁵³ Nagao T, Meguro S, Soga S, Otsuka A, Tomonobu K, Fumoto S, Chikama A, Mori K, Yuzawa M, Watanabe H, Hase T, Tanaka Y, Tokimitsu I, Shimasaki H, Itakura H. Tea catechins suppress accumulation of body fat in humans. *J Oleo Sci* 2001; 50: 717– 728.
- ⁵⁴ Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P, Vandermander J. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. *Am J Clin Nutr*. 1999 Dec;70(6):1040-5.
- ⁵⁵ Zheng G, Sayama K, Okubo T, Juneja LR, Oguni I. Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. *In Vivo*. 2004 Jan-Feb;18(1):55-62.
- ⁵⁶ Maki KC, Reeves MS, Farmer M, Yasunaga K, Matsuo N, Katsuragi Y, Komikado M, Tokimitsu I, Wilder D, Jones F, Blumberg JB, Cartwright Y. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. *J Nutr*. 2009 Feb;139(2):264-70. Epub 2008 Dec 11.
- ⁵⁷ Sae-Tan S, Rogers CJ, Lambert JD. Voluntary exercise and green tea enhance the expression of genes related to energy utilization and attenuate metabolic syndrome in high fat fed mice. *Mol Nutr Food Res*. 2014 May;58(5):1156-9. doi: 10.1002/mnfr.201300621. Epub 2013 Dec 27
- ⁵⁸ Justin D Roberts, Michael G Roberts, Michael D Tarpey, Jack C Weekes, and Clare H Thomas. The effect of a decaffeinated green tea extract formula on fat oxidation, body composition and exercise performance. Roberts et al. *Journal of the International Society of Sports Nutrition* (2015) 12:1. DOI 10.1186/s12970-014-0062-7
- ⁵⁹ Ngondi JL, Djiotsa EJ, Fossouo Z, Oben J: Hypoglycaemic effect of the methanol extract of *Irvingia gabonensis* seeds on streptozotocin diabetic rates. *Afr J Trad Cam* 2006, 3(4):74-77
- ⁶⁰ Jones J, Barrick C, Kim K, Lindner J, Blondeau B, Fujimoto Y et al. (April 2005). "Deletion of PPAR γ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance". *Proc. Natl. Acad. Sci. U.S.A.* 102 (17): 6207–12. doi:10.1073/pnas.0306743102. PMC 556131. PMID 15833818
- ⁶¹ Oben J, Ngondi JL, Blum K: Inhibition of *Irvingia gabonensis* seed extract (OB131) on adipogenesis as mediated via down regulation of the PPAR γ and Leptin genes and up-regulation of the adiponectic gene. *Lipids in Health and Disease* 2008, 7:44
- ⁶² Oben JE, Ngondi JL, Momo CN, et al. The use of *Cissus quadrangularis*/*Irvingia gabonensis* combination in the management of weight loss: a double-blind placebo-controlled study. *Lipids Health Dis* 2008;7:12
- ⁶³ Schmidt, C., Abicht, A., Krampfl, K., Voss, W., Stucka, R., Mildner, G., Petrova, S., Schara, U., Mortier, W., Bufler, J., Huebner, A., and Lochmuller, H. Congenital myasthenic syndrome due to a novel missense mutation in the gene encoding choline acetyltransferase. *Neuromuscul. Disord*. 2003;13(3):245-251
- ⁶⁴ Huseini HF, Larijani B, Heshmat R, et al. The efficacy of *Silybum marianum* (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. *Phytother Res* 2006;20:1036-9
- ⁶⁵ Hussain, S. A. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. *J. Med. Food* 2007;10(3):543-547
- ⁶⁶ Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (*Camellia sinensis*). *Ann Intern Med* 2006;144:68-71
- ⁶⁷ Anon. Milk thistle: Effects on liver disease and cirrhosis and clinical adverse effects. Summary, Evidence Report/Technology Assessment: Number 21, September 2000. Agency for Healthcare Research and Quality, Rockville, MD. Available at: <http://www.ahrq.gov/clinic/epcsums/milktsu.htm>
- ⁶⁸ Nemezc G. Green tea. *US Pharm* 2000;May:67-70.
- ⁶⁹ Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. *Cancer* 2003;97:1442-6
- ⁷⁰ Yates AA, Schlicker SA, Sutor CW. Dietary reference intakes: The new basis for recommendations for calcium and related nutrients, B vitamins, and choline. *J Am Diet Assoc* 1998;98:699-706.
- ⁷¹ Shrouts EP. Essential nature of choline with implications for total parenteral nutrition. *J Am Diet Assoc* 1997;97:639-46.
- ⁷² Boerth J, Strong KM. The clinical utility of milk thistle (*Silybum marianum*) in cirrhosis of the liver. *J Herb Pharmacother*. 2002;2(2):11-7.

Practitioner Dietary Supplement Reference Guide – 3rd Edition

⁷³ Pisters KM, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. *J Clin Oncol* 2001;19:1830-8.

⁷⁴ Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. *Cancer* 2003;97:1442-6.